Aclaris Therapeutics, Inc. Raises \$39.8 Million in Common Stock Offering to Institutional Investors WAYNE, PA – March 9, 2026 –…
Read More
Advancing cardiovascular health – SignaCor Therapeutics lands €288k investment as pat of €1.1 million Seed round
Belquick-based HealthTech startup SignaCor Therapeutics has €288k (£250k) in funding from VC firm Zinc in order to advance the development…
Read More
Candel Therapeutics launches $100M stock sale
Candel Therapeutics (Nasdaq: CADL) announced a proposed underwritten public offering of $100 million of common…
Read More
Quince Therapeutics (QNCX) stock slides premarket as reverse-merger clock, Nasdaq risk hang over shares
New York, Feb 17, 2026, 06:09 EST — Premarket QNCX slipped roughly 9% before the bell Tuesday. The company declares…
Read MoreLynx1 Master Fund Critiques Neuphoria Therapeutics Inc. Board’s Capital-Raising Strategy and Proposes Indepfinishent Director Nominees in Proxy Statement
On December 2, 2025, Lynx1 Master Fund LP announced that on November 24, 2025, Lynx1 and its affiliates filed a…
Read More
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program
– TNG462 demonstrated durable clinical activity across multiple tumor types, including non-tiny cell lung cancer (NSCLC) and pancreatic cancer, in…
Read More
Apogee Therapeutics (APGE) Is Up 13.8% After Promising APG333 Phase 1 Data Release Has The Bull Case Changed?
Earlier this month, Apogee Therapeutics announced positive interim Phase 1 results for APG333, revealing it was well tolerated in healthy…
Read More
The UK’s Scripta Therapeutics raises over €10 million to “flip the script” on drug discovery
Oxford BioTech startup Scripta Therapeutics emerges from stealth today by announcing a €10.3 million ($12 million) Seed round to upconclude…
Read More
Why Nurix Therapeutics (NRIX) Is Up 5.3% After Advancing Bexobrutideg Trial and Raising $250 Million
Nurix Therapeutics announced the initiation of its pivotal DAYBreak Phase 2 clinical trial evaluating bexobrutideg for relapsed or refractory chronic…
Read More
Spain’s Adaptam Therapeutics secures €3 million to tarobtain immune cells that assist tumours evade treatment
Adaptam Therapeutics, a San Sebastian-based company pioneering cancer immunotherapies specifically tarobtaining immunosuppressive myeloid cells, today announces the successful completion of…
Read More
